Over 60% of world's HIV-1 infected individuals are in sub-Saharan African nations. In particular Zambia has one of the highest rates of infection. As in many developing countries, the academic medical community in Zambia is not enviable, and due to limited funds, meaning the emphasis in training most often focuses on clinical medicine rather than on biomedical research. Consequently, little is done to significantly improve patient care and laboratory support services. Faculty at the University of Zambia's School of Medicine (UNZA) and the University Teaching Hospital (UTH), located in the country's capital of Lusaka, recognize that to address the problem in rising cases of AIDS-associated diseases, including AIDS associated mental disorders and neurological diseases, a common and coordinated training and research program in NeuroAIDS is needed. Without such a program, it will be extremely difficult to develop the research capacity and infrastructure necessary to truly impact the country's healthcare agenda and to position faculty to compete for future research funding so that they can fully and efficiently participate in future research initiatives in HIV-associate neurological diseases. In recognition of this, we have now added this International Core as a new Core for the CHAIN Center, where we will work with our colleagues in Zambia to address these important issues.

Public Health Relevance

In this Core we will institute a training and research program to study HIV-associated neurological diseases in Zambia. This proposed program is unique, teaming Zambian and U.S. researchers to address the emerging problems of neurological diseases in HIV-infected individuals in understudied regions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
2P30MH062261-11
Application #
8195025
Study Section
Special Emphasis Panel (ZMH1-ERB-M (03))
Project Start
Project End
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
11
Fiscal Year
2011
Total Cost
$123,796
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Hu, Guoku; Liao, Ke; Yang, Lu et al. (2017) Tat-Mediated Induction of miRs-34a & -138 Promotes Astrocytic Activation via Downregulation of SIRT1: Implications for Aging in HAND. J Neuroimmune Pharmacol 12:420-432
Stauch, Kelly L; Emanuel, Katy; Lamberty, Benjamin G et al. (2017) Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals. J Neurovirol 23:795-807
Li, Weizhe; Gorantla, Santhi; Gendelman, Howard E et al. (2017) Systemic HIV-1 infection produces a unique glial footprint in humanized mouse brains. Dis Model Mech 10:1489-1502
Kevadiya, Bhavesh D; Bade, Aditya N; Woldstad, Christopher et al. (2017) Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging. Acta Biomater 49:507-520
Araínga, Mariluz; Edagwa, Benson; Mosley, R Lee et al. (2017) A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology 14:17
Sandkovsky, Uriel; Podany, Anthony T; Fletcher, Courtney V et al. (2017) Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. J Antimicrob Chemother 72:200-204
Gnanadhas, Divya Prakash; Dash, Prasanta K; Sillman, Brady et al. (2017) Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. J Clin Invest 127:857-873
Shahnaz, Gul; Edagwa, Benson J; McMillan, JoEllyn et al. (2017) Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. Nanomedicine (Lond) 12:99-115
Edagwa, Benson; McMillan, JoEllyn; Sillman, Brady et al. (2017) Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv 14:1281-1291
Guo, Dongwei; Zhou, Tian; Araínga, Mariluz et al. (2017) Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine. J Acquir Immune Defic Syndr 74:e75-e83

Showing the most recent 10 out of 346 publications